|
ARB 304
|
ARB 305
|
ARB 336
|
ARB 354
|
ARB 355
|
SESSION 1
1:00 – 1:45 pm
|
Georgeanne Hodges, Pharm.D
Optimizing Glycemic Control in the Inpatient Setting- Applying the 2019 ADA Guidelines
|
Lacy Patterson, Pharm.D
No More Depresso Thanks To Zulresso: Brexanolone for Treatment of Postpartum Depression
|
Vanessa Brown, Pharm.D
Oral versus Intravenous Antibiotics in the Treatment
of Osteomyelitis
|
Joshua Knebel, Pharm.D
Assessing Amantadine Efficacy in Post Traumatic Brain Injury Aggression/Agitation
|
Zachary Moszczenski, Pharm.D
Deliriously Managing Delirium in the ICU
|
1:45 – 1:55 pm
|
Travel time to accommodate movement between rooms
|
||||
SESSION 2
1:55 – 2:40 pm
|
James Unverferth, Pharm.D
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and their Role in Type 1 Diabetes
|
Marisa Roberts, Pharm.D
Patience is a Virtue: Management of Patent Ductus Arteriosus with Watchful Waiting
|
Michele McCloskey, Pharm.D
Eculizumab for the Treatment
of Atypical Hemolytic Uremic Syndrome (aHUS)
|
Justin Xu, Pharm.D Role and Timing of Restarting Anticoagulation in Patients with Intracranial Hemmorrhage |
N/A
|
2:40 – 2:50 pm
|
Travel time to accommodate movement between rooms
|
||||
SESSION 3
2:50 – 3:40 pm
|
Ryan Goff, Pharm.D
PCSK9 Inhibitors and Statins and Their Potential Role in Increasing Type 2 Diabetes
|
Emily Henningsen, Pharm.D
Shifting to Symbicort? Budesonide/formoterol as needed for mild asthma
|
Adam Robinson, Pharm.D
Expanding treatment options for relapsed and refractory acute myeloid leukemia
|
Shannon Jones, Pharm.D
Evaluating the use of neuromuscular blocking agents in acute respiratory distress syndrome
|
Casey Dubrawka, Pharm.D
Use of Hepatitis C Positive Kidney Allografts in Hepatitis C Negative Recipients
|
Registration is free, but is required in advance. Due to limited space, only those participants who register before 12:00 PM on Tuesday, December 17, 2019 will be able to request parking access on campus.
To request parking, please first register for your desired sessions. Then, complete the parking questionnaire using the link above, or complete your parking request by clicking here. If you do not request parking on our campus, or if you do not submit your requst by the deadline, you will be re-directed upon arrival.
Paper copies of handouts will be provided in each room as well as electronically on this website. Copies of PowerPoint slides are not provided. To access the handouts electronically, participants should ensure they are logged in before accessing this event. Click the + symbol beside the session, which will expand the module. A clickable text link to download the handout as a PDF file will be present.
ATTENDANCE
All participants will be required to sign in on the paper sheets, located within each room. Paper sign-in sheets will be reconciled against electronic credit reporting on this website. Sessions you did not attend will be removed from your account within two weeks following the seminars.
CPE CREDIT
Participants must claim all CPE credit electronically. Participants may claim no more than one 45-minute session for each time block. To do so, participants must complete an online evaluation for those sessions attended no later than two weeks following the sessions. Participants must be logged on and registered in order to view and complete the evaluation(s). Only ONE session may be claimed for each time block. If multiple concurrent sessions are claimed, or if a session is claimed that is not reflected on the paper sign in sheets, the offending participant forfeits CE credit.
SPECIAL ACCOMMODATIONS
Attendees of all abilities are welcome to participate. If you require reasonable accommodations, please notify us in advance so that we may secure resources as soon as possible. Every effort will be made to make accommodations where necessary.
Date: Dec 19, 2019 01:00 PM - 04:00 PM
Fee
CE Hours
Activity Type
- Knowledge
Target Audience(s)
- Pharmacists
Accreditation(s)
St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. To learn more about the specific program information, including universal activity numbers (UAN's) and learning objectives, please expand the modules below. Following successful completion of an evaluation, CE credit will be automatically reported to NABP through the CPE Monitor system, using the NABP ePID numbers and date of birth (MMDD) stored in participants' user profiles. Follow this link to learn more about CPE Monitor and the credit reporting process » Participants are responsible for ensuring receipt of credit; no credit can be corrected or awarded if more than 60 days have passed from the date of the event or if the home study is expired.
It is the policy of St. Louis College of Pharmacy at the University of Health Sciences and Pharmacy in St. Louis, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating in this program are expected to disclose to the program audience any real or apparent conflicts of interest related to the content of the presentation.
|
Speaker(s)/Author(s)
Georgeanne Hodges, Pharm.D. |
Activity Number
0033-0000-19-145-L01-PCE Hours
Location
Speaker(s)/Author(s)
Lacy Patterson, Pharm.D. |
Activity Number
0033-0000-19-146-L01-PCE Hours
Location
Speaker(s)/Author(s)
Vanessa Brown, Pharm.D. |
Activity Number
0033-0000-19-140-L01-PCE Hours
Location
Speaker(s)/Author(s)
Joshua Knebel, Pharm.D. |
Activity Number
0033-0000-19-142-L01-PCE Hours
Location
Speaker(s)/Author(s)
Zachary Moszczenski, Pharm.D. |
Activity Number
0033-0000-19-138-L01-PCE Hours
Location
Speaker(s)/Author(s)
James Unverferth, Pharm.D. |
Activity Number
0033-0000-19-132-L01-PCE Hours
Location
Speaker(s)/Author(s)
Marisa Roberts, Pharm.D. |
Activity Number
0033-0000-19-147-L01-PCE Hours
Location
- Raina, R., et al. (2019), Atypical Hemolytic?Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment. Ther Apher Dial, 23: 4-21.
- Franchini, M. (2015). Atypical hemolytic uremic syndrome: from diagnosis to treatment. Clinical Chemistry and Laboratory Medicine (CCLM), 53(11), pp. 1679-1688. Retrieved 26 Nov. 2019, from doi:10.1515/cclm-2015-0024
- Fakhouri, F., et al. (2016). "Terminal Complement Inhibitor Eculizumab in Adult Patients With Atypical Hemolytic Uremic Syndrome: A Single-Arm, Open-Label Trial." American Journal of Kidney Diseases 68(1): 84-93.
Speaker(s)/Author(s)
Michele McCloskey, Pharm.D. |
Activity Number
0033-0000-19-143-L01-PCE Hours
Location
Speaker(s)/Author(s)
Justin Xu, Pharm.D. |
Activity Number
0033-0000-19-133-L01-PCE Hours
Location
Speaker(s)/Author(s)
Ryan Goff, Pharm.D. |
Activity Number
0033-0000-19-144-L01-PCE Hours
Location
Speaker(s)/Author(s)
Emily Henningsen, Pharm.D. |
Activity Number
0033-0000-19-134-L01-PCE Hours
Location
Few pharmacists have encountered these agents yet in clinical practice and/or have been exposed to the data surrounding the use of these agents in RR FLT3+ AML. This seminar will assess the new literature surrounding FLT3 inhibitors and their use in RR FLT3+ AML in order to attempt to establish the place of these agents in clinical practice.
Speaker(s)/Author(s)
Adam Robinson, Pharm.D. |
Activity Number
0033-0000-19-137-L01-PCE Hours
Location
Speaker(s)/Author(s)
Shannon Jones, Pharm.D. |
Activity Number
0033-0000-19-135-L01-PCE Hours
Location
Speaker(s)/Author(s)
Casey Dubrawka, Pharm.D. |